Humasis (CEO Cha Jeong-hak), a company specializing in on-site rapid testing, announced on the 29th that it had terminated a contract to supply Corona 19 diagnostic kits worth 136.6 billion won with Celltrion earlier this year.
According to the announced contract details, regarding 44.7 billion won of the initial contract amount of regarding 133.6 billion won on January 22 was fulfilled according to the contract, and 91.9 billion won was canceled, and the fulfillment rate is 32.69%.
Humasis announced on April 28 that it extended the contract period from April 30 to December 31 to respond to the US COVID-19 diagnostic kit market environment.
An official from Humasis said during the contract period, “Celltrion made unreasonable, unreasonable, and excessive demands.” We will prepare active responses, including claims for damages.”
“The total contract size of Humasis and Celltrion’s COVID-19-related products is regarding 401.2 billion won, of which 297.9 billion won, or 74.26%, has been fulfilled,” he said. .
Meanwhile, Humasis received a suitability judgment from the Ministry of Food and Drug Safety through an examination of the in vitro diagnostic medical device technical documents of ‘Humasis COVID-19 RT-PCR Kit’.
